The Substantia Nigra Is a Powerful Pain Control Center — But Only Through Mu Opioid Receptors
Mu opioid agonist injected into the substantia nigra produced pain relief comparable to the periaqueductal gray, while delta and kappa agonists were ineffective — identifying a new brain pain control site.
Quick Facts
What This Study Found
Mu-selective agonist DAGO injected into the substantia nigra produced antinociception comparable to the periaqueductal gray. Delta and kappa agonists had no effect.
Key Numbers
How They Did This
Rats received bilateral microinjections of selective opioid agonists into the substantia nigra. Pain was tested using tail-flick and hot-plate methods. Antagonists confirmed receptor specificity.
Why This Research Matters
This study identifies the substantia nigra as a key brain region for opioid pain control. Previously, most attention focused on the periaqueductal gray. Knowing that multiple brain areas contribute to pain relief could improve pain treatment strategies.
The Bigger Picture
Identifying additional brain pain control centers expands our understanding of how the brain manages pain. The substantia nigra's dual role in movement and pain may explain why Parkinson's patients commonly experience both movement and pain problems.
What This Study Doesn't Tell Us
Animal study in rats using direct brain injections. This invasive method is not applicable to human treatment. The substantia nigra is primarily known for movement control, and effects on motor function could confound pain testing.
Questions This Raises
- ?Does the pain control function of the substantia nigra deteriorate in Parkinson's disease?
- ?Could nigral mu receptor targeting provide a new approach to pain management?
Trust & Context
- Key Stat:
- Mu-only pain control in substantia nigra Only mu agonists produced antinociception in the substantia nigra, with potency comparable to the periaqueductal gray
- Evidence Grade:
- Preliminary animal study using direct brain microinjection. Demonstrates receptor specificity but invasive technique.
- Study Age:
- Published in 1991. The substantia nigra's role in pain processing has been further confirmed and is relevant to Parkinson's pain research.
- Original Title:
- The effects of bilateral intranigral microinjection of selective opioid agonists on behavioral responses to noxious thermal stimuli.
- Published In:
- Brain research, 557(1-2), 136-45 (1991)
- Authors:
- Baumeister, A A
- Database ID:
- RPEP-00186
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why is finding a new pain control center important?
The more brain pain centers we identify, the more therapeutic targets we have. If conventional pain drugs target one center, knowing about others could lead to combination approaches or treatments for patients who don't respond to standard therapy.
How does this relate to Parkinson's disease?
The substantia nigra degenerates in Parkinson's. If this region also controls pain, its degeneration could explain why up to 80% of Parkinson's patients experience chronic pain — and why it often doesn't respond well to standard pain treatments.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00186APA
Baumeister, A A. (1991). The effects of bilateral intranigral microinjection of selective opioid agonists on behavioral responses to noxious thermal stimuli.. Brain research, 557(1-2), 136-45.
MLA
Baumeister, A A. "The effects of bilateral intranigral microinjection of selective opioid agonists on behavioral responses to noxious thermal stimuli.." Brain research, 1991.
RethinkPeptides
RethinkPeptides Research Database. "The effects of bilateral intranigral microinjection of selec..." RPEP-00186. Retrieved from https://rethinkpeptides.com/research/baumeister-1991-the-effects-of-bilateral
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.